Waters Corporation ROIC

ROIC of WAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2020 was 32.48% (a -10.35% decrease from previous year)
  • Annual ROIC for 2019 was 36.23% (a -23.21% decrease from previous year)
  • Annual ROIC for 2018 was 47.18% (a -4.47% decrease from previous year)
  • Twelve month ROIC ending December 30, 2020 was 32.48% (a 2.72% increase compared to previous quarter)
  • Twelve month trailing ROIC decreased by -0.43% year-over-year
Trailing ROIC for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
32.48% 31.62% 31.93% 32.62%
Visit stockrow.com/WAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of Waters Corporation

Most recent ROICof WAT including historical data for past 10 years.

Interactive Chart of ROIC of Waters Corporation

Waters Corporation ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 32.48%
2019 36.23%
2018 47.18%
2017 49.39%
2016 29.68%
2015 30.77%
2014 30.06%
2013 28.13%
2012 32.84%
2011 51.2%
2010 34.19%

Business Profile of Waters Corporation

Sector: Healthcare
Industry: Diagnostics & Research
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.